公开(公告)号：US20190231752A1

公开(公告)日：2019-08-01

申请号：US16380243

申请日：2019-04-10

Applicant: Novartis AG

Inventor： Virender Singh AULAKH ,  Anthony CASAREZ ,  Xiaodong LIN ,  Mika LINDVALL ,  Glenn MCENROE ,  Heinz Ernst MOSER ,  Folkert RECK ,  Meiliana TJANDRA ,  Robert Lowell SIMMONS ,  Aregahegn YIFRU ,  Qingming ZHU

IPC: A61K31/427 ,  A61K31/433 ,  C07D487/04 ,  A61K31/4545 ,  A61K31/496 ,  C07D417/14 ,  A61K31/4439 ,  A61K31/454 ,  A61K45/06

CPC classification number: A61K31/427 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K45/06 ,  C07D417/14 ,  C07D487/04 ,  Y02A50/473 ,  Y02A50/481

Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.

公开(公告)号：US20210079015A1

公开(公告)日：2021-03-18

申请号：US16764525

申请日：2018-11-16

Applicant: Novartis AG

Inventor： Jiping FU ,  Mika LINDVALL ,  James R. MANNING ,  Glenn MCENROE

IPC: C07D498/04

Abstract: The invention provides compounds of Formula (I) n R3b Z W Q R3a H Y N R1 R4 R2 O (I) as described herein, along with stereoisomeric forms salts, hydrates, solvates, and salts thereof and pharmaceutical compositions and pharmaceutical combinations containing such compounds, as well as methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus (HBV), and for reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US20200276169A1

公开(公告)日：2020-09-03

申请号：US16823485

申请日：2020-03-19

Applicant: Novartis AG

Inventor： Virender Singh AULAKH ,  Anthony CASAREZ ,  Xiaodong LIN ,  Mika LINDVALL ,  Glenn MCENROE ,  Heinz Ernst MOSER ,  Folkert RECK ,  Meiliana TJANDRA ,  Robert Lowell SIMMONS ,  Aregahegn YIFRU ,  Qingming ZHU

IPC: A61K31/427 ,  A61K45/06 ,  C07D487/04 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/454 ,  C07D417/14

Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.